• New Delhi
  • 23 August 2013
  • Interviews
  • By Rahul Koul

“We are part of a bigger plan to eliminate Kala Azar”

With its new drug development program (synergies with One World Health), PATH is developing treatments that target neglected tropical diseases. During a recent interaction with BioSpectrum, Dr Raj Shankar Ghosh, technical director for PATH India, spoke

drrajshankarghosh

PATH is an international nonprofit organization that transforms global health through innovation. Its mission is to improve the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors.

Q: Please tell about your activities in India?

Dr Ghosh: PATH began its work in India the late 1990s, bringing governments, communities, private-sector companies, and experienced public health practitioners together to address some of the country's most crucial health problems. One of our first large projects was the USAID funded Program for Advancements of Commercial Technology-Child and Reproductive Health (PACT-CRH). In early 2000, the scope of our India program expanded with a major immunization initiative for Andhra Pradesh state. Today, with offices in Bhopal, Lucknow, Mumbai, New Delhi, Patna, and Hyderabad, PATH's India projects focus on immunization, HIV/AIDS, injection safety, and microbicides.
In Indian context, the organization is also involved in strengthening routine immunization services and introducing new vaccines (including hepatitis B vaccine) into India's Universal Immunization Programme. We are also the secretariat of the India Injection Safety Coalition, for which we were a founding member.

We have also been in the business of clinical development of vaccines over a long period of time. In 2012, the institute of one world health which was another product development department merged with PATH. We work closely with the department of biotechnology (DBT), Clinical Development Services Agency (CDSA), and Translational Health Science and Technology Institute ( THSTI). With CDSA, we have been involved in developing the clinical development capacity of clinical researchers in India over the past three years.

Q: Please tell about the Japanese Encephalitis vaccine and its implementation in the Indian national immunization programme?

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X